- Home
- HIO vs ITOS Comparison
HIO vs ITOS Comparison
Compare HIO & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIO
- ITOS
- Stock Information
- Founded
- HIO 1993
- ITOS 2011
- Country
- HIO United States
- ITOS United States
- Employees
- HIO N/A
- ITOS N/A
- Industry
- HIO Finance/Investors Services
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HIO Finance
- ITOS Health Care
- Exchange
- HIO Nasdaq
- ITOS Nasdaq
- Market Cap
- HIO 380.4M
- ITOS 381.2M
- IPO Year
- HIO N/A
- ITOS 2020
- Fundamental
- Price
- HIO $3.98
- ITOS $10.28
- Analyst Decision
- HIO
- ITOS Hold
- Analyst Count
- HIO 0
- ITOS 6
- Target Price
- HIO N/A
- ITOS $10.60
- AVG Volume (30 Days)
- HIO 305.3K
- ITOS 773.7K
- Earning Date
- HIO 01-01-0001
- ITOS 08-07-2025
- Dividend Yield
- HIO 10.33%
- ITOS N/A
- EPS Growth
- HIO N/A
- ITOS N/A
- EPS
- HIO N/A
- ITOS N/A
- Revenue
- HIO N/A
- ITOS $35,000,000.00
- Revenue This Year
- HIO N/A
- ITOS N/A
- Revenue Next Year
- HIO N/A
- ITOS N/A
- P/E Ratio
- HIO N/A
- ITOS N/A
- Revenue Growth
- HIO N/A
- ITOS 177.89
- 52 Week Low
- HIO $3.52
- ITOS $4.80
- 52 Week High
- HIO $4.03
- ITOS $18.13
- Technical
- Relative Strength Index (RSI)
- HIO 58.50
- ITOS 65.14
- Support Level
- HIO $3.97
- ITOS $10.24
- Resistance Level
- HIO $3.94
- ITOS $10.41
- Average True Range (ATR)
- HIO 0.03
- ITOS 0.12
- MACD
- HIO -0.00
- ITOS -0.04
- Stochastic Oscillator
- HIO 72.22
- ITOS 75.00
About HIO Western Asset High Income Opportunity Fund Inc.
Western Asset High Income Oppor Fd Inc is a diversified closed-end management investment company. The company's primary objective is to seek high current income and the secondary objective is capital appreciation. It invests a majority of its net assets in high-yield corporate debt securities and the rest in common stock equivalents, including options, warrants, and rights. The company invests in securities of companies from various sectors such as energy, technology, utilities, industrials, communications, finance, and capital goods among others.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.